Sponsor study identifier
observational
43
1 country
6
Study Start
September 25, 2023
Actual (reported)Primary Completion
June 30, 2025
Actual (reported)Study Completion
June 30, 2025
Actual (reported)The study is being conducted to validate the clinical performance of the T-TAS 01 HD assay for measurement of thrombogenicity in patients with thrombocytopenia receiving a platelet transfusion.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2025
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 25, 2023
Actual (reported)October 11, 2023
Actual (reported)October 17, 2023
Actual (reported)June 30, 2025
Actual (reported)June 30, 2025
Actual (reported)Baseline thrombogenicity
Proportion of T-TAS 01 HD area under the curve (AUC) \< 700
Baseline
Improvement in thrombogenicity
Difference in proportion of T-TAS 01 HD AUC \< 700 between pre-transfusion and post-transfusion measurements
Day 1 after platelet transfusion
Correlation with bleeding risk
Day 1 after transfusion
Comparison of pre-and post-transfusion thrombogenicity
Day 1 after platelet transfusion
Comparison of pre-and post-transfusion thrombogenicity
Day 1 after platelet transfusion
Prediction of future platelet transfusions
Day 1 after platelet transfusion
Ostensibly healthy subjects with a normal platelet count and without a history of hemostasis abnormalities, for establishing expected values for quality control
Subjects with thrombocytopenia who are planned to receive a platelet transfusion who have pre-transfusion and post-transfusion blood samples collected for testing
Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
* Ostensibly healthy subjects with a normal platelet count and without a history of hemostasis abnormalities, for establishing expected values for quality control (N = up to 50) * Subjects with thrombocytopenia who are planned to receive a platelet transfusion who have pre-transfusion and post-transfusion blood samples collected for testing (N = 50; up to 90 will be enrolled in the event that some subjects do not receive platelet transfusions after enrollment)
San Francisco General Hospital
San Francisco, California, 94112, United States
University of Colorado Anschutz Medical Campus
Denver, Colorado, 80217, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Duke University
Durham, North Carolina, 27710, United States
University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
Jeffrey Dahlen, Ph.D.
Hikari Dx, Inc.
43 participants (actual enrollment reported by the registry).
First Submitted
October 11, 2023
First Posted
October 17, 2023
Study Start
September 25, 2023
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
June 30, 2025
Actual (reported)Study Completion
June 30, 2025
Actual (reported)Last Updated
July 28, 2025
Record last verified: 2025-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: